BELITE BIO, INC (BLTE)

Pharmaceutical Preparations · market cap $6.7B · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-09 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Belite Bio, Inc. (BLTE) is a small-cap pharmaceutical company (~25 employees, ~$5.9B market cap) with a single clinical asset: tinlarebant, currently in Phase 3 trials for Stargardt disease (STGD1), a rare inherited retinal dystrophy. The company has no disclosed revenue, and the investment case is a binary bet on the Phase 3 readout expected around mid-2027.

The catalyst path

2026-11-09 (est.)Earningsimp 5/10
2027-02-11 (est.)PDUFA · Tinlarebantimp 9/10
2027-06-30 (est.)Phase 3 · Tinlarebantimp 9/10

Pipeline

Asset	Phase	Indication
Tinlarebant	Phase 3	STGD1

Price & technical context

3-month

+6.6%

6-month

-3.3%

12-month

+123.5%

52-wk range

$74.06–$193.61

vs 50-day MA

-0.9%

vs 200-day MA

+2.0%

Realized vol

53.4%

Max drawdown

-36.6%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for BLTE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.